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Abstract
Background: Glycated haemoglobin (HbA1c) is an important outcome measure in diabetes clinical trials. For
multicentre designs, HbA1c can be measured locally at participating centres or by sending blood samples to a
central laboratory. This study analyses the agreement between local and central measurements, using 1-year follow-up
data collected in a multicentre randomised controlled trial (RCT) of newly diagnosed children with type I diabetes.
Methods: HbA1c measurements were routinely analysed both locally and centrally at baseline and then at 3, 6, 9 and
12 months and the data reported in mmol/mol. Agreement was assessed by calculating the bias and 95 % limits of
agreement, using the Bland-Altman analysis method. A predetermined benchmark for clinically acceptable margin of
error between measurements was subjectively set as ±10 % for HbA1c. The percentage of pairs of measurements that
were classified as clinically acceptable was calculated. Descriptive statistics were used to examine the agreement within
centres. Treatment group was not considered.
Results: Five hundred and ninety pairs of measurement, representing 255 children and 15 trial centres across four
follow-up time points, were compared. There was no significant bias: local measurements were an average of 0.
16 mmol/mol (SD = 4.5, 95 % CI −0.2 to 0.5) higher than central. The 95 % limits of agreement were −8.6 to 9.
0 mmol/mol (local minus central). Eighty percent of local measurements were within ±10 % of corresponding
central measurements. Some trial centres were more varied in the differences observed between local and
central measurements: IQRs ranging from 3 to 9 mmol/mol; none indicated systematic bias.
Conclusions: Variation in agreement between HbA1c measurements was greater than had been expected
although no overall bias was detected and standard deviations were similar. Discrepancies were present across all
participating centres. These findings have implications for the comparison of standards of clinical care between
centres, the design of future multicentre RCTs and existing quality assurance processes for HbA1c measurements.
We recommend that centralised HbA1c measurement is preferable in the multicentre clinical trial setting.
Trial registration: Eudract No. 2010-023792-25, registered on 4 November 2010.
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Background
In 2014, approximately 3.2 million people living in the
United Kingdom were diagnosed with diabetes [1–5].
Globally, 12 % of all health care expenditure is spent on
diabetes care [6]. In the United Kingdom, the greatest
percentage of NHS costs, and burden to patients, comes
from long-term vascular complications [7].
Circulating blood glucose attaches to haemoglobin and
concentrations of the resulting glycated haemoglobin, or
‘HbA1c’, reflect levels of blood glucose in the preceding
8–12 weeks. In 1993 The Diabetes Control and Compli-
cations Trial (DCCT) reported conclusive evidence that
glycaemic control (GC), reported as mean HbA1c, is a
critical determinant of the risk of long-term vascular
complications [8]. More recently, variability of HbA1c
over time has been identified as an important, additional
risk factor for vascular disease. During the course of
the DCCT, a patient in the 97.5th centile of HbA1c
variability was three times more likely to develop
diabetes-related eye disease and more than twice as
likely to develop diabetes-related kidney disease that
of a patient in the 2.5th centile [9].
HbA1c is measured routinely in clinical services to
guide individual diabetes care. It is also a robust clinical
outcome for clinical trials, being largely influenced by
circulating blood glucose levels. The only caveat is that
subjects with blood disorders, such as sickle cell an-
aemia, may have more rapid haemoglobin turnover, lead-
ing to HbA1c concentrations providing underestimates
of true blood glucose control. It is usual practice to ex-
clude these individuals from clinical trials in which
HbA1c is an outcome measure, and for other estimates
of blood glucose control that are independent of haemo-
globin turnover to be used in routine clinical practice.
Standards of diabetes care and clinical outcomes are
reported annually at a national level, and can be com-
pared between centres through the National Diabetes
Audit and the National Paediatric Diabetes Audit. There
are many factors that influence GC, of which one is the
quality of clinical services.
The International Federation of Clinical Chemistry
and Laboratory Medicine (IFCC) has worked to stand-
ardise measurement of HbA1c at an international level
[10] and HbA1c assays have been calibrated against the
IFCC-standardised values since June 2009. This process
of standardisation should in theory remove the need for
centralised measurement of HbA1c for either clinical or
research purposes. The main analytical methods used for
the measurement of HbA1c include affinity chromatog-
raphy, immunoassay, cation exchange chromatography,
and capillary electrophoresis [11]. Due to the variety of
methods available, there can be significant differences
between results obtained, as observed on the national
external quality assurance programmes (due in part to
haemoglobin variants and sample interferences such as
bilirubin and lipids).
Due to the importance of GC in determining future
risk of diabetes-related complications, it is an important
endpoint used within clinical trials. In the multicentre
study setting, HbA1c can be measured in three ways: at
point of contact (POC), e.g. on the ward or in a clinic
using bedside portable instrumentation; by sending
blood samples to local hospital laboratories; or by send-
ing blood samples to a central laboratory. Measurements
made at POC and local laboratories are logistically eas-
ier, less costly and represent the pragmatic reality of
HbA1c measurement in routine care. However, a central
laboratory provides a single standardised testing facility
that may provide more consistent results for primary
endpoints leading to higher validity of conclusions and
allow comparison of outcomes between participating
centres. However, this approach incurs higher costs in
trial implementation, and may represent an additional
burden for paediatric patients, in whom it may be diffi-
cult to obtain sufficient blood for dual analyses.
SCIPI is a clinical trial randomising newly diagnosed
children to two methods of insulin delivery [12]: multiple
daily injections or continuous pump infusion. The study,
funded by the National Institutes for Health Research
(NIHR) Health Technology Assessment (HTA) programme
aims to compare the effect of insulin regimen on HbA1c
measurements 12 months post diagnosis. The initial appli-
cation to the NIHR HTA requested costs to support central
laboratory analysis of HbA1c. This was to provide uniform-
ity and standardisation of the method of measurement.
However, the funding decision stated that ‘HbA1c should
be measured according to the national protocol and could
be done locally’. Despite arguments to support central
laboratory analysis the trial was funded to support
local costs only.
The Trial Management Group (TMG) expressed con-
cerns about the limitations of this approach and so funds
were eventually identified to include centralised HbA1c
testing. The central laboratory began collecting blood
samples 19 months after the study opened. This meant
that the first participants’ results were not from the cen-
tral laboratory. Furthermore, the pragmatic nature of the
study meant that local results for follow-up appoint-
ments were usually obtained using portable instrumenta-
tion. Although POC devices are calibrated to the same
standards as laboratory-based methods, this introduces
another level of uncertainty. Also, if the sample was
taken at a patient home visit then local results may have
been unobtainable but a sample was sent for central
analysis. The necessity for both local and central analysis
was evident within the clinical trial protocol and was
stressed during the training of staff collecting samples at
participating sites throughout the duration of the trial
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and included publicity for this issue in the trial newslet-
ter and email reminders of its importance.
This study examines the agreement between locally
and centrally measured HbA1c in a multicentre trial set-
ting. The aim of this analysis is to inform the statistical
analysis plan for the final analysis of SCIPI and future
trial designs. These data also give us helpful insights into
the validity of comparing HbA1c values between clinical
centres as a measure of quality of care.
Methods
At the time of this agreement analysis 294 children and
young people aged 7 months to 15 years, who had been
newly diagnosed with type I diabetes mellitus, had been
randomised in a 1:1 ratio to receive either continuous
subcutaneous insulin infusion (CSII) or multiple daily
injections (MDI) of insulin. Fifteen UK trial centres were
involved in the study.
The first patient was randomised on 31 May 2011
and central laboratory analysis became available on 21
January 2013. The trial completed recruitment at the
end of March 2015 with 294 patients randomised but
some follow-up data collection was occurring at the
time of this analysis (due to be completed by the end
of March 2016).
HbA1c was collected prior to the start of the rando-
mised treatment and then at follow-up appointments at
3, 6, 9 and 12 months. Data regarding the randomised
allocations was not required for this analysis as this
study investigated agreement independent of treatment
received.
Measurement of HbA1c
The capillary blood samples were collected from finger-
pricks into small capillary tubes and were analysed in
two separate locations: locally – the majority were ana-
lysed using portable instrumentation at outpatient
clinics; and centrally – at the clinical pathology labora-
tory at Alder Hey Children’s NHS Foundation Trust,
using a Siemens DCA 2000 machine. Transportation of
samples to the central laboratory was by two possible
modes: either through the post; or via bespoke courier
systems to ensure that the samples would be received
the next day.
Quality assurance of the measurement of HbA1c
Portable instrumentation is calibrated regularly with
local laboratories. All laboratories involved in the meas-
urement of HbA1c are obliged to participate in external
quality assurance schemes, ensuring that laboratories
with equivalent equipment are able to produce results
that are comparable to each other. For almost all HbA1c
measurements (local and central), the biochemical meth-
odology employed was immunoassay.
Data extraction
Pairs of HbA1c measurements (one local and one
central) were extracted from the SCIPI database in
September 2015. Each pair of measurements was re-
quired to be from a single blood sample (samples
taken on different days were excluded). Unusually
large disagreements (>20 mmol/mol) were queried
and, if unresolved, were reported on but excluded
from the analysis to limit bias of results.
Units of measurement of HbA1c
HbA1c measured locally was usually recorded in two
units of measurement: mmol/mol and percent (percent-
age of total haemoglobin). HbA1c measured at the cen-
tral laboratory (at Alder Hey) was recorded in mmol/
mol only, according to the IFCC-aligned standards for
reporting HbA1c [10]. From 1 June 2011 the clinical
standard unit of measurement for HbA1c became
mmol/mol. This paper reports agreement using mmol/
mol.
The formula used for conversion between the two
units of measurement is:
HbA1c %ð Þ ¼ HbA1c mmol=molð Þ
10:929
þ 2:15;
where HbA1c was only recorded in percent, the conver-
sion formula above was used to calculate a value in
mmol/mol. Where both units of measurement were
present, a check was made on the accuracy of the con-
version by comparing derived conversions from the for-
mula above with actual conversions recorded in the
database. Where there was a discrepancy of more than
1 mmol/mol or 0.1 % (i.e. when not accounted for due
to rounding), data entry was queried. For unresolved
queries, the source unit of measurement was sought and
taken to be the true measurement, and the other was de-
rived using the conversion formula. If the source unit of
measurement could not be verified, the pair of measure-
ments was excluded.
Clinically acceptable agreement
Prior to analysis and specified within the statistical ana-
lysis plan, limits of clinically acceptable agreement were
defined by the chief investigator to be that local mea-
surements were within ±10 % mmol/mol of central
measurements:
0:9 HbA1cLocal < HbA1cCentral < 1:1 HbA1cLocal:
Limits are justified by the potential differences in clin-
ical outcomes that a difference of 10 % can imply – in
the Diabetes Control and Complication Research Group
study [8], the relationship between HbA1c and the risk
of developing microvascular complications, and the rate
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of progression of microvascular complications, was seen
as a continuum across the range of GC. This was most
marked at the higher levels of HbA1c: the 10 % differ-
ence in HbA1c between 10 % and 9 % was associated
with a 25 % reduction in the rate of progression of retin-
opathy. Within patient observations they suggest that a
difference in HbA1c of 10 % is clinically significant:
those patients who reduced their HbA1c by 10 % (for
example, 9.0 % to 8.1 %) reduced their risk of acquiring
retinopathy and nephropathy by 39 % and 25 %,
respectively.
Statistical methods
Prior to undertaking the agreement analysis, a statistical
analysis plan was developed by BA and agreed by CG.
Simple demographics were summarised (gender, age and
social deprivation score) for both the full cohort of chil-
dren randomised in SCIPI and the subset that had at
least one valid pair of HbA1c measurements included in
this analysis. The Bland-Altman analysis of agreement
method was used to compare local and central measure-
ments. For each pair of measurements, the difference
(D) (local measurement minus central) and the mean
(M) was calculated. Heteroscedasticity (variance of D in-
creasing/decreasing with increasing M) was examined
through plotting limits of agreement (LOA) graphs.
One-way analysis of variance (ANOVA) was used to
check whether within-subject variance of differences was
significantly different to between subject variance – i.e.
to check whether the repeated measures nature of the
data needed to be accounted for in the agreement ana-
lysis. The percentage of pairs within clinically acceptable
limits was calculated for both units of measurement
using the predetermined limits described below. De-
scriptive statistics were used to examine the agreement
within centres. Finally, the time-lag between date of col-
lection of blood sample and date of laboratory analysis
was investigated as a possible explanation for poor
agreement. All analyses were implemented using SAS
software version 9.3.
Results
Sample characteristics
Of 294 children randomised for the trial, 255 had at
least one pair of measurements of HbA1c included in
this analysis (see below and Fig. 1 for detailed break-
down of exclusions). Of the 255 children included in this
analysis, the mean (standard deviation (SD)) age was 8.9
(4.1) years and 51.6 % were male. They were similar in
demography to the full sample of 294 children (aged 9
(4.1) years, 52.4 % male) (see Table 1). Children were re-
cruited from 14 trial centres across England and from 1
centre in Wales.
A total of 590 pairs of measurements of HbA1c were
included, all from follow-up: 139 at 3 months, 157 at
6 months, 143 at 9 months and 151 at 12 months. At
baseline, local and central measures were taken on dif-
ferent days: locally (usually sent to the local laboratory)
at diagnosis, and centrally at randomisation/entry into
the trial. Children included in this analysis had a median
of two valid pairs of measurements. Of the 15 trial
centres, 6 had low sample sizes (less than 20 valid
pairs) and the remaining 9 had between 21 and 108
valid pairs.
Exclusions
There was potential for 1004 follow-up HbA1c measure-
ments to be available at the time of the data snapshot of
which 414 could not be included (see Fig. 1). Three hun-
dred and seventy four of these were because at least one
of the pair was missing (35 appointments were not
attended; 35 local measurements were either not avail-
able or not measured; 65 appointments took place prior
to the commencement of central laboratory testing; for
172 samples the quantity of blood sent to the central la-
boratory was not sufficient to enable a test; 8 samples
sent to the central laboratory were clotted; and 59 were
missing for some other the reason). Thirty pairs were
excluded because they could not be confirmed to be
from the same blood sample. In 10 pairs there were unre-
solved data-validity queries: 8 pairs were found to differ by
more than 20 mmol/mol – there was a maximum discrep-
ancy of 40 mmol/mol; 2 pairs had unresolved questionable
unit conversions recorded.
Bias and limits of agreement
Table 2 provides the results of HbA1c in mmol/mol at
each follow-up time. The means and SDs are similar for
local and central measurements both overall and by time
point.
On average, local measurements were 0.16 mmol/mol
higher than central (95 % CI −0.2 to 0.5). This bias was
not statistically significant, showing that local mea-
surements were not systematically higher or lower
than central measurements. The 95 % LOA were cal-
culated to be −8.6 to 9.0 mmol/mol (see Fig. 2 and
Table 3).
Verification of assumptions
The assumptions of the Bland-Altman LOA analysis
were found to hold: differences between local and cen-
tral measurements were symmetrically distributed and
with an approximate bell shape; and there was no indi-
cation of serious heteroscedasticity – i.e. no marked in-
crease/decrease in variance of differences with
increasing HbA1c (see Fig. 2). There was no evidence
that the variance of differences was different for
Arch et al. Trials  (2016) 17:517 Page 4 of 8
measurements on the same child compared with measure-
ments on different children (one-way ANOVA p = 0.15) –
for this reason, the repeated measures nature of the data
was not taken into account in calculating LOA. Trial
centre was ignored for the main agreement analysis, as the
number of valid pairs of measurements for 6 out of 14
centres was small (less than 20), and the remaining 9
centres did not display strong heterogeneity in levels of
agreement (Fig. 3, Table 4).
Clinically acceptable agreement
The proportion of pairs where the local measurement
was within ±10 % of the central measurement was 80 %
(see Table 3 for results by site).
Table 1 Sample characteristics
All children randomised Children with at least one valid pair of measurements
N Summary statistics n Summary statistics
Available sample size 294 255
Males: n (%) 292 153 (52.4 %) 254 131 (51.6 %)
Age: mean (SD) 292 9.0 (4.1) 254 8.9 (4.1)
Participating centres 15 15
Number of follow-up appointments attended: 294 - 255 2 (1,3)a
Total 294 1371 255 590a
Median (IQR) per child 294 5(4,5) 255 2 (1,3)a
aTime points where a valid pair of measurements were available. IQR interquartile range, SD standard deviation
Fig. 1 Flowchart showing sample sizes (n) and number of pairs of measurements (m) available for analysis
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Centre-specific agreement
Centres varied in levels of agreement (see Table 4 and
Fig. 3). Of the six centres with larger numbers of valid
pairs of measurements (m > 30) (centres 2, 4, 8, 9, 13
and 14), one had a median difference that was negative,
two had a median of 0 and three had positive medians.
All six had both negative and positive differences, indi-
cating that no centre incurred a clear systematic bias.
Centre 5 was very variable with an interquartile range
(IQR) for differences of 7.5 mmol/mol – 29 % of pairs
from this centre were classified as clinically unacceptably
different.
Time-lags between blood collection and central analysis
There was a median time-lag of 2 days (IQR 1–4 days)
between the collection of blood samples and their ana-
lysis at the central laboratory. There was no correlation
(r = −0.02) detected between time-lag and difference be-
tween local and central measurements.
Discussion
These data suggest that there are discrepancies in mea-
surements of HbA1c depending on whether blood sam-
ples are analysed locally using POC equipment, or sent
to a central laboratory; but that these discrepancies are
not biased. It is also important to note that the SDs of
measurements were similar for local and central measure-
ments at every time point, showing that power calcula-
tions would not be affected by location of measurement.
In this study setting, it was found that 95 % of local and
central measurements were within a fairly wide margin of
discrepancy: ±9 mmol/mol and that one in five (20 %)
pairs were classified as clinically unacceptably different.
This has implications for the validity and reliability of
measurements for clinical decision-making for individual
patients.
In the course of this study, some data entry errors,
and errors in the conversion from one unit of measure-
ment to another were found – though these were de-
tected through the querying process. Only a handful of
queried data anomalies could not be verified and these
were excluded from analysis. Centre-specific agreement
did vary, though there was no centre-specific systematic
bias evident. Some centres may have had more unreli-
able local measurement methods than others or there
may have been more errors with data entry.
The time-lag between blood sampling and analysis at
the central laboratory was not associated with levels of
agreement, suggesting that there were no issues affecting
measurement related to storage and transport of blood
samples.
Discrepancies between HbA1c measurements can
sometimes be explained by issues with instrumentation
(lot-to-lot variation with HbA1c cartridges; variation be-
tween instrumentation makes and models; differences in
sample collection devices; measurement errors by users;
rogue cartridges within a batch).
Table 2 Mean (SD) glycosylated haemoglobin (HbA1c) measured locally and centrally overall and by time point (valid pairs of data only)
Number of pairs of measurements Local (mmol/mol) Central (mmol/mol)
All data 590 55.2 (13.0) 55.1 (13.1)
By time point:
3 months 139 50.0 (12.9) 49.5 (12.2)
6 months 157 54.0 (12.9) 54.2 (13.5)
9 months 143 58.5 (12.5) 57.9 (12.3)
12 months 151 58.3 (11.7) 58.5 (12.3)
Fig. 2 Limits of agreement (LOA) graph (95 % LOA lines: dashed,
bias: red line)
Table 3 Agreement statistics: local minus central glycosylated
haemoglobin (HbA1c)
HbA1c (mmol/mol)
Bias
Mean difference 0.16
SD of differences 4.49
95 % CI for mean (−0.20, 0.52)
95 % limits of agreement −8.6, 9.0
Percentage within clinically acceptable limits 92.9 %
CI confidence interval, SD standard deviation
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This study does not provide evidence that central mea-
surements are more accurate or more reliable, but rather
that the measurement of HbA1c is variable between
methods of analysis. In the routine practice of diabetes
care, local measurement at clinics incurs lower costs and
is convenient for decision-making; in the clinical trial
setting, however, a single systematic centralised method-
ology would be preferable to eliminate any chance that
differences in measurement methodology, or levels of
training, affect the estimation of effect sizes. Pragmatic-
ally, this study provides no reason why local measure-
ments could not be used in place of missing central
measurements, given that there would be no overall bias
incurred.
Conclusions
This study shows that a central laboratory provides a
standardised measurement methodology for recording
HbA1c during follow-up, and that the results obtained
are an unbiased representation of HbA1c measured lo-
cally at trial centres. Overall, the mean and standard de-
viation of measurements were similar for both sources
of measurement, meaning that power calculations would
not be affected by choice of source of measurement.
However, there was found to be a wide spread of differ-
ences between local and central measurements for indi-
vidual blood samples. This means that in some cases,
post-diagnosis decision-making could be quite different if
based on local measurements compared with central ones.
For the purposes of developing the SCIPI analysis plan
the primary analysis will use central laboratory measures
where available and use local results when this is not the
case. This is based on the lack of systematic bias and the
consistency in the size of the means and SDs across time
points and scales.
Future investigators, and those using measures of
HbA1c as indicators of standards of routine clinical care
need to be aware of the variability that persists in the
measurement of HbA1c across centres within the United
Kingdom, despite a commitment to working according
to the IFCC initiative for standardisation of measuring
and reporting HbA1c. A single central laboratory
Fig. 3 Boxplots showing the distribution of differences between
local and central measurements, by trial centre
Table 4 Agreement by centre
Centre code Number of children Number of valid pairs
of measurements
Median (IQR) difference (local–central)
(mmol/mol)
Local within ±10 % of central (%)
1 8 13 0 (−3,3) 85 %
2 16 47 −1 (−3,1) 94 %
3 2 6 2 (0,3) 83 %
4 29 68 1 (−2,3) 78 %
5 17 28 2 (−2.5,5) 71 %
6 6 18 −1 (−2,2) 89 %
7 1 2 −1 (−3,1) 100 %
8 52 108 0 (−3,3) 79 %
9 41 94 0 (−3,2) 82 %
10 7 21 0 (−2,3) 90 %
11 7 9 0 (0,3.3) 89 %
12 10 25 0 (−2,1) 88 %
13 19 51 3 (0,5) 69 %
14 34 85 1 (−1,3) 76 %
15 6 15 −2 (−4,5) 80 %
All 255 590 0 (−2,3) 80 %
IQR interquartile range
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provides a uniform methodology that, whilst more ex-
pensive, removes some of the complexity of sources of
variation inherent in the multicentre local measurement
approach.
Endnotes
1CTRC: Clinical Trials Research Centre, University of
Liverpool.
2SCIPI: Randomised controlled trial of continuous
subcutaneous insulin infusion compared to multiple
daily injection regimens in children and young people at
diagnosis of type I diabetes mellitus.
Abbreviations
GC: Glycaemic control; HbA1c: Glycated haemoglobin; IQR: Interquartile
range; LOA: Limits of agreement; POC: Point of contact; SD: Standard
deviation
Acknowledgements
None to add.
Funding
SCIPI was funded by the Health Technology Assessment (HTA) programme of
the National Institute for Health Research (NIHR): Project reference: 08/14/39.
Availability of data and materials
The data for these analyses are available on request from the lead author.
Authors’ contributions
All authors read and approved the final manuscript. BA carried out the
analysis and wrote the ‘Statistical methods’, the ‘Results’ and much of the
‘Discussion’ section, and drafted the manuscript. JB wrote part of the
‘Background’ section and reviewed the manuscript. AM helped with data
issues and reviewed the manuscript. JWG reviewed the manuscript. PN
contributed the biochemistry methodology and reviewed the manuscript.
CG raised the original question and led the statistical team contributing to
the statistical analysis plan, analyses and manuscript.
Authors’ information
BA is a statistician at the CTRC.1 JB is a consultant endocrinologist, and the
SCIPI2 CI. AM is the SCIPI2 trial statistician at the CTRC1. JWG is a professor in
paediatric endocrinology at the University of Cardiff, and a coinvestigator
and PI for SCIPI2. PN is a consultant biochemist at Alder Hey Children’s
Hospital. CG is Deputy Head of the Department of Biostatistics at the
University of Liverpool and Deputy Director of the CTRC1.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
SCIPI was approved by the accredited National Research Ethics Committee
North-West – Liverpool East on 31 March 2011 (Ref 10/H1002/80). The study
protocol follows the principles of the Declaration of Helsinki and the Medical
Research Involving Human Subjects Act (WMO), and it is compliant with the
International Conference on Harmonisation of Good Clinical Practice (ICH-GCP).
All participants gave informed consent prior to enrolment in the study.
Disclaimers
Department of Health Disclaimer
The views and opinions expressed therein are those of the authors and do
not necessarily reflect those of the HTA, the NIHR, the NHS or the Department
of Health.
Funding disclaimer
This project was funded by the National Institute for Health Research HTA
08/14/39.
Author details
1Department of Biostatistics, The University of Liverpool, Liverpool L69 3BX,
UK. 2Alder Hey Children’s NHS FT, East Prescott Road, Liverpool L12 2AP, UK.
3Professor in Paediatric Endocrinology & Honorary Consultant, Division of
Population Medicine, School of Medicine, Cardiff University, Heath Park,
Cardiff CF14 4XN, UK. 4Department of Biochemistry, Alder Hey Children’s
NHS FT, East Prescott Road, Liverpool L122AP, UK.
Received: 30 June 2016 Accepted: 4 October 2016
References
1. Office for National Statistics (ONS), UK. Population estimates for UK, England
and Wales, Scotland and Northern Ireland, Mid-2014. 2016.
2. QOF 2014–2015. Report for England v1.1. 2015.
3. Quality and Outcomes Framework (QOF) 2014-2015, Information Services
Division(ISD) Scotland. 2015.
4. General Medical Services Contract. Quality and Outcomes Framework
Statistics for Wales, 2014–15. 2015
5. Department of Health, Social Services and Public Safety, Northern Ireland,
UK. Quality and Outcomes Framework Statistics for Northern Ireland 2014/
15. 2015.
6. International Diabetes Federation (IDF). IDF Diabetes atlas, 7th ed. 2015.
7. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and
future costs of type 1 and type 2 diabetes in the UK, including direct health
costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):
855–62. doi:10.1111/j.1464-5491.2012.03698.x.
8. The Diabetes Control and Complications Trial Research Group. The effect of
intensive treatment of diabetes on the development and progression of
long-term complications in insulin-dependent diabetes mellitus. N Engl J
Med. 1993;329(14):977–86. doi:10.1056/NEJM199309303291401.
9. Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular
complications in type 1 diabetes: data from the Diabetes Control and
Complications Trial. Diabetes Care. 2008;31(11):2198–202. doi:10.2337/
dc08-0864.
10. Jeppsson JO, Kobold U, Barr J, Finke A, Hoelzel W, Hoshino T, et al.
Approved IFCC reference method for the measurement of HbA1c in human
blood. Clin Chem Lab Med. 2002;40(1):78–89. doi:10.1515/cclm.2002.016.
11. John EEG. Analyte monograph: HbA1c. 2012
12. Blair J, Gregory JW, Hughes D, Ridyard CH, Gamble C, McKay A, et al. Study
protocol for a randomised controlled trial of insulin delivery by continuous
subcutaneous infusion compared to multiple daily injections. Trials. 2015;
16(1):1–9. doi:10.1186/s13063-015-0658-5.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Arch et al. Trials  (2016) 17:517 Page 8 of 8
